^
No biomarker
Rhabdomyosarcoma
dactinomycin
Sensitive
:
A1
No biomarker
Rhabdomyosarcoma
IE
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
VAC
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + etoposide IV + cyclophosphamide oral + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
trabectedin
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
ADX-2191
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
vinorelbine tartrate
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
topotecan
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
irinotecan
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
temozolomide + irinotecan + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
cyclophosphamide oral + vinorelbine tartrate
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
carboplatin + etoposide oral
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
vincristine + dactinomycin
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
irinotecan + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
cyclophosphamide oral + topotecan
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide + cyclophosphamide oral + vincristine
Sensitive
:
A2
BRAF-MAD1L1 fusion
Rhabdomyosarcoma
anlotinib
Resistant
:
C4
HRAS mutation
Rhabdomyosarcoma
tipifarnib
Sensitive
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our